Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00965822Phase 2Completed

A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population

Role: lead

NCT01468376Phase 1Terminated

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

Role: lead

NCT00966225Phase 1Completed

LIP-01 in Hypercholesterolemia

Role: lead

NCT01456182Phase 1Withdrawn

Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

Role: lead

NCT00240461Phase 3Completed

Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors

Role: collaborator

NCT00726401Phase 2Completed

A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis

Role: lead

All 6 trials loaded